FEC stats reveal pharma donations to presidential runners
February 12, 2016Sales and Marketing
Stats from the Center for Responsive Politics and the Federal Election Commission (FEC), have revealed the extent of donations from the …
UK patients get early access to Opdivo for kidney cancer
February 12, 2016Medical Communications, Sales and Marketing
Bristol Myers-Squibb’s Opdivo (nivolumab) will be available through the Early Access to Medicines Scheme (EAMS) as a monotherapy to UK …
Amgen’s Kyprolis now available to UK multiple myeloma patients
February 12, 2016Medical Communications, Sales and Marketing Amgen, Kyprolis, multiple myeloma
Amgen has announced the UK launch of Kyprolis (carfilzomib) in combination with Revlimid (lenalidomide) and dexamethasone for the treatment of …
Biosimilars: Can the US catch up in 2016?
February 12, 2016Medical Communications, Sales and Marketing Eli Lilly, Enbrel, FDA, Neulasta, Novartis, Pfizer, Sandoz, Zarxio, biosimilars
What are biosimilars? Biosimilars are essentially the biological equivalent of generic drugs to their branded small-molecule counterparts (what Ibuprofen is …
GSK fined millions over deals to delay generic competition
February 12, 2016Medical Communications, Sales and Marketing GSK seroxat
GlaxoSmithKline has been fined £37.6m by the UK Competition & Markets Authority (CMA) for paying two generic drugmakers to delay …
Sandoz buys rights to Pfizer biosimilar
February 12, 2016Medical Communications, Research and Development, Sales and Marketing Pfiizer, Sandoz, biosimilars
Sandoz has announced further expansion to its biosimilars programme with the acquisition of the European rights to Pfizer’s Remicade (infliximab) …
Incyte to stop Jakafi pancreatic, colorectal cancer drug trials
February 11, 2016Research and Development Incyte, Jakafi, Jakavi, Novartis, Pancreatic cancer, colorectal cancer
Incyte said today that it is terminating its JANUS clinical trial programme testing blood cancer drug Jakafi in solid tumours …
ABPI appoints Mike Thompson as new chief executive
February 11, 2016Medical Communications
The Association of the British Pharmaceutical Industry (ABPI) has appointed former GlaxoSmithKline executive Mike Thompson as its new chief executive …
Genomics England enters bioinformatics partnership with Illumina
February 11, 2016Research and Development Genomics england, Illumia
Genomics England has announced a new partnership with US-based sequencing specialist Illumina to develop a platform and knowledge base that …
Alzheimer’s disease market set to double to $10.4 Billion by 2021
February 11, 2016Research and Development, Sales and Marketing Alzheimer's disease
The Alzheimer’s disease market will more than double from just under $5 billion in 2014 to an estimated $10.4 billion …
EMA accepts Sandoz Neulasta biosimilar for review
February 11, 2016Research and Development Amgen, Neulasta, Novartis, Sandoz
Sandoz says the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for its proposed biosimilar to Amgen’s …
Sandoz’s Carol Lynch elected to chair European Biosimilars Group
February 10, 2016Medical Communications biosimilars
The European Generic Medicines Association (EGA) has elected Carol Lynch, global head of Biopharmaceuticals & Oncology Injectables at Sandoz, as …
MSD’s Zepatier approval could spell end of Gilead’s Hep C dominance, says analyst
February 10, 2016Sales and Marketing AbbVie, Drug pricing, Gilead Sciences, MSD, Solvadi, Viekira Pak, harvoni, hepatitis C
The introduction of MSDs’ recently FDA-approved drug Zepatier (elbasvir/grazoprevir) to the hepatitis C treatment space will shake up a market …
NICE publishes new myeloma guidance
February 10, 2016Medical Communications, Research and Development Farydak, Novartis, multiple myeloma
NICE has set out best practice for the diagnosis, monitoring and treatment of myeloma, in new guidelines published today. Myeloma …
Novartis says CDF proposals place “unreasonable” risk on pharma
February 10, 2016Medical Communications, Research and Development, Sales and Marketing Cancer Drugs Fund, NHS England, NICE, Novartis
Novartis has criticised some of the proposed changes to the way in which the UK Cancer Drugs Fund (CDF) is …
Heptares announces positive early-stage dementia trial results
February 10, 2016Research and Development Alzheimer's, Alzheimers, Heptares, dementia, schizophrenia
Heptares has announced positive findings from its Phase 1b clinical study with its investigational drug HTL9936 as a treatment for …
FDA advisory committee recommends approval of Remicade biosimilar
February 10, 2016Research and Development, Sales and Marketing FDA, Pfizer, Remicade, biosimilar, celltrion
An FDA advisory panel yesterday voted overwhelmingly in favour of approving CT-P13- Celltrion’s biosimilar version of Johnson&Johnson’s blockbuster arthritis drug …
New breast cancer initiative brings together pharma and Europe’s top researchers
February 9, 2016Medical Communications, Research and Development Pfizer, breast cancer
The UK charity Breast Cancer Now (BCN) has announced a new initiative seeking to bring together Europe’s top researchers and …
Pfizer names leadership team post-Allergan merger
February 9, 2016Manufacturing and Production, Sales and Marketing Allergan, Pfizer
Pfizer has announced the executive leadership team for the combined Pfizer and Allergan business once the $160 billiion merger deal …
INTERVIEW: Tackling the Zika threat
February 9, 2016Manufacturing and Production, Medical Communications Zika, vaccines
The Zika outbreak which started in Brazil and spread rapidly to other south American countries and beyond has taken the …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
